admin – Page 3851 – Get News Story

Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Diabetic Retinopathy Pipeline Insight” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Retinopathy Treatment Landscape. Click here to read more @ Diabetic Retinopathy Pipeline Outlook

Key Takeaways from the Diabetic Retinopathy Pipeline Report

In March 2025:- Vantage Biosciences Ltd announced a study to evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy of Non-Proliferative Type (NPDR).
In March 2025:- Invirsa Inc. announced a phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR [Part 1].
In March 2025:- Incepta Pharmaceuticals Ltd conducted a study to to Compare Efficacy & Safety Between Ranibizumab 10mg/ml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection.
In March 2025:- EyePoint Pharmaceuticals Inc. announced a study of Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME).
DelveInsight’s Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment.
The leading Diabetic Retinopathy Companies such as Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
Promising Diabetic Retinopathy Pipeline Therapies such as Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.

Discover groundbreaking developments in Diabetic Retinopathy therapies! Gain in-depth knowledge of key Diabetic Retinopathy clinical trials, emerging drugs, and market opportunities @ Diabetic Retinopathy Clinical Trials Assessment

Diabetic Retinopathy Emerging Drugs Profile

Tarcocimab tedromer: Kodiak Sciences

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak’s proprietary Antibody Biopolymer Conjugate (“”ABC””) Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak’s objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new durability agent to improve outcomes for patients with retinal vascular diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of diabetic retinopathy.

OTT166: Ocuterra Therapeutics

Nesvategrast (OTT166) is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, nesvategrast selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, nesvategrast eye drops have demonstrated preliminary evidence of tolerability and biological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diabetic retinopathy.

APX3330: Apexian Pharmaceuticals

APX3330 is a first-in-class, small molecule, oral inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1). With a novel dual mechanism of action, APX3330 blocks the downstream pathways those involving angiogenesis (VEGF) and inflammation (NFkB) to decrease abnormal activation of both angiogenesis, and of inflammatory pathways that are implicated across several ocular diseases, including DR, DME, and age-related macular degeneration (AMD). APX3330 has shown a favorable safety and tolerability profile in 12 clinical trials conducted in healthy, hepatitis, cancer, and diabetic subjects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of diabetic retinopathy.

OTX-TKI: Ocular Therapeutix

OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetic retinopathy.

The Diabetic Retinopathy Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment.
Diabetic Retinopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market

Stay informed about the Diabetic Retinopathy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Retinopathy Unmet Needs

Diabetic Retinopathy Companies

Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.

Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Transform your understanding of the Diabetic Retinopathy Pipeline! See the latest progress in drug development and clinical research @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspectives

Scope of the Diabetic Retinopathy Pipeline Report

Coverage- Global
Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.
Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Diabetic Retinopathy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diabetic Retinopathy– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
KSI-301: Kodiak Sciences
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
RGX 314: Regenxbio Inc
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
OTX-TKI: Ocular Therapeutix
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diabetic Retinopathy Key Companies
Diabetic Retinopathy Key Products
Diabetic Retinopathy- Unmet Needs
Diabetic Retinopathy- Market Drivers and Barriers
Diabetic Retinopathy- Future Perspectives and Conclusion
Diabetic Retinopathy Analyst Views
Diabetic Retinopathy Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Pharmaceutical Packaging Market – Size, Segmental analysis, Regional Overview, Company Market share, Forecast, 2025 – 2028

“The pharmaceutical packaging market is evolving with innovations in sustainable materials, smart packaging, and stringent regulations. Rising demand for biologics and personalized medicine further drives growth. Ensuring safety, compliance, and efficiency will be key to shaping the market’s future expansion.”

The pharmaceutical packaging market is evolving with innovations in sustainable materials, smart packaging, and stringent regulations. Rising demand for biologics and personalized medicine further drives growth. Ensuring safety, compliance, and efficiency will be key to shaping the market’s future expansion.

The global pharmaceutical packaging market size is estimated to be USD 132.0 billion in 2023 and is projected to reach USD 269.9 billion at a CAGR of 15.4% during the forecast period. The reports 2025 research report offers an analytical view of the industry by studying different factors like pharmaceutical packaging market growth, consumption volume, Market Size, Revenue, Market Share, Market Trends, and pharmaceutical packaging industry cost structures during the forecast period from 2025 to 2028. The surge in urbanization, evolving lifestyles, increased disposable income, a growing preference for sustainable packaging, and global awareness of diseases are driving the expansion of the pharmaceutical packaging market. However, challenges include the elevated costs of raw materials used in manufacturing packaging products. Financial constraints, lack of information, outdated equipment, lack of proper staff, and awareness of proper healthcare practices are the major challenges that limit access to healthcare services. Opportunities arise from the rising demand for sustainable packaging, as it reduces waste and minimizes the impact of pharmaceutical products on the environment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=890

“Plastic bottles is largest growing segment on the basis of type, in terms of value, during the forecast period.”

The demand for plastic bottles in the pharmaceutical packaging market is due to several factors including improved barrier properties, low water absorption, high impact strength, transparency, high dimensional stability, resistance to strain, heat, and flame resistance. Plastic bottles offer pharmaceutical companies convenience in transportation due to their ease of handling and reduced risk of breakage compared to glass bottles. Their durability minimizes the potential for product loss and safety concerns associated with breakages, making them a preferred choice in the pharmaceutical plastic bottle market. The use of plastic bottles aligns with stringent government regulations, underscoring their suitability for pharmaceutical packaging.

“Primary packaging form is largest growing segment on the basis of packaging type, in terms of value, during the forecast period.”

Various factors contribute to the increasing demand for the primary packaging segment in the pharmaceutical packaging market. These include the increasing prevalence of diseases, advancements in biotechnology and novel therapies, innovations in materials, rising healthcare expenditures, diversification of product portfolios, adherence to regulatory standards and quality assurance, as well as consumer preferences. The protection of pharmaceutical products from external factors such as light, air, moisture, and contaminants is essential for maintaining their stability and efficacy, making primary packaging a critical component.

“Plastic is largest growing segment on the basis of raw material, in terms of value, during the forecast period.”

The increasing prominence of plastic raw materials in the pharmaceutical packaging market can be attributed to several factors. Firstly, plastics provide a versatile platform for designing and implementing a diverse range of packaging solutions tailored to meet specific pharmaceutical requirements. Additionally, the cost-effectiveness of plastics, both in production and transportation, contributes to overall economic efficiency. The lightweight characteristics of plastic materials facilitate easier handling, resulting in reduced transportation costs and minimized environmental impact. Moreover, plastics boast excellent barrier properties, offering effective protection for pharmaceutical products against external factors such as moisture and contaminants.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=890

“Oral drug delivery is largest growing segment on the basis of drug delivery, in terms of value, during the forecast period.”

Several factors contribute to the dominance of oral drug delivery in the pharmaceutical packaging market. Firstly, a significant portion of pharmaceutical preparations is intended for oral consumption, making oral drug delivery packaging the largest segment in the market. Secondly, oral drug delivery packaging is cost-effective, offering a practical and economical choice for pharmaceutical companies. Thirdly, the flexibility in designing dosage forms makes oral drug delivery an ideal option for pharmaceutical companies. Lastly, the increasing prevalence of chronic diseases and the growing global demand for pharmaceutical products have fueled the expansion of the oral drug delivery packaging market.

“North America is largest growing segment on the basis of region, in terms of value, during the forecast period.”

North America has the largest market share in the pharmaceutical packaging market in terms of value.

Europe has the second largest market share in the pharmaceutical packaging market in terms of value. With prominent consumers like the US, Canada, and Mexico leading the trend, the region thrives on increased construction activities and is a hub of major packaging manufacturers. The pharmaceutical packaging market in North America is experiencing growth due to rapidly evolving pharmaceutical therapies, new drug innovations, and the increasing demand for smart packaging. In North America, essential market drivers include a heightened demand for diverse drug delivery methods, the integration of additional features in packaging products, and the development of packaging solutions with child-resistant and senior-friendly features.

Pharmaceutical Packaging Companies

Berry Global Group, Inc. (US), Gerresheimer AG (Germany), Amcor Plc (Switzerland), Schott AG (Germany), and AptarGroup, Inc. (US) are some of the established players in the pharmaceutical packaging market. The growing trend of rising consumer awareness for safe and secure packaging solutions is driving the market. These players have adopted various strategies such as mergers & acquisitions, joint ventures, and expansion to strengthen their market position.

Berry Global Group, Inc. is a leader in plastic packaging. It operates through three business segments, namely, engineered materials; health, hygiene & specialties; and consumer packaging. Pharmaceutical devices and packaging are offered under the consumer packaging segment. The company provides non-woven film and lamination for a wide range of medical & pharmaceutical applications and for healthcare packaging needs. It offers storage plastic components such as containers, food service products, closures and over caps, and bottle & prescription containers and tubes. The company serves various industries, such as food, healthcare, shipping & transportation, building & construction, and personal care. It manufactures and supplies its packaging solutions to the US, Canada, Mexico, Belgium, France, Spain, the UK, Italy, Germany, Australia, Brazil, Argentina, Colombia, Malaysia, India, China, and the Netherlands. The company operates more than 300 facilities around the globe and has about 47,000 employees.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=890

Gerresheimer AG is one of the leading companies specializing in medicine packaging, drug delivery devices, and comprehensive solutions for the pharmaceutical industry. The company is primarily dedicated to the production and supply of glass and plastic packaging solutions on a global scale for the pharmaceutical and healthcare sectors. It functions through three key business segments: plastics & devices, primary packaging glass, and advanced technologies. Gerresheimer AG conducts its pharmaceutical packaging operations through the primary packaging glass and plastics & devices segments. With a presence in 16 countries across three continents—Europe, the Americas, and Asia—the company operates 36 manufacturing plants. These locations include Poland, Mexico, Switzerland, Singapore, India, the Czech Republic, Brazil, Belgium, China, France, Denmark, Spain, North Macedonia, and the US. Employing more than 10,000 individuals, the company has a workforce of 4,504 in the plastics & devices segment and 5,333 in the primary packaging glass segment.

Amcor PLC is a leading packaging company for food, beverage, pharmaceutical, medical, home & personal care, and other products. It is primarily involved in the manufacturing and marketing of flexible packaging, rigid containers, and specialty cartons and closures by using raw materials such as polymers, aluminum foils, and fibers. The company operates through two business segments, namely, Amcor flexibles and Amcor Rigid Plastics. Amcor flexibles business produces flexible packaging for food, beverage, pharmaceutical, medical, home, and personal care, and other products, whereas Amcor’s rigid business develops and produces rigid containers and closures for food, beverage, spirits, home and personal care, and healthcare products. Amcor has a wide range of healthcare packaging for oral, dermal, medical devices, hospital packaging, ophthalmic & vision care, pulmonary, intravenous fluid, and injectables. It performs its operations through subsidiaries in the EMEA (Europe, Middle East, and Africa), the Americas, and Asia Pacific. The company operates through 220 production sites in more than 40 countries. It has 78 sales, corporate, other offices, and research sites with more than 44,000 employees. Amcor flexibles operate through 175 plants in 43 countries with more than 40,000 employees and Amcor rigid operates 50 plants in 11 countries with more than 6,000 employees.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/pharmaceutical-packaging-market-890.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pharmaceutical Packaging Market – Size, Segmental analysis, Regional Overview, Company Market share, Forecast, 2025 – 2028

CE-LINK Intelligent BMS System Offers Eight Protection Mechanisms to Guard Battery Safety

With the growing demand for reliable and efficient portable power solutions, portable power stations have become indispensable for outdoor sports enthusiasts, emergency backup power, and off-grid living. Ensuring the safety and longevity of batteries is a top priority for users. CE-LINK’s well-designed, intelligent Battery Management System (BMS) plays an important role in maintaining the health and performance of portable power stations, preventing potential hazards, and optimizing energy efficiency.

What is an Intelligent BMS?

An intelligent BMS is an advanced control system that monitors, manages, and protects the batteries in a portable power station. It oversees key parameters such as voltage, current, temperature, and state of charge (SoC) to optimize battery performance continuously. Unlike traditional BMS, intelligent BMS combines intelligent data analysis technology to realize condition monitoring and real-time data analysis functions.

The main role of intelligent BMS is to ensure safety and efficiency. Lithium-ion batteries commonly used in portable power stations are prone to risks such as overcharging, overheating, and short circuits. The intelligent BMS reduces these risks by dynamically adjusting the charge rate, balancing the batteries, and shutting down the system in the event of an anomaly. It also extends battery life by preventing deep discharges and optimizing charge cycles.

Eight protection mechanisms

Undervoltage Protection

When the battery voltage drops too low, the BMS alerts automatically cut off the power supply to prevent over-discharging the battery, leading to capacity loss and irreversible damage.

Over Voltage Protection

To prevent overcharging from swelling the battery, when the battery reaches its maximum safe voltage threshold, the system will stop charging to avoid potential damage to internal components.

Overcurrent Protection

During charging and discharging, the current can spike quickly. If the BMS detects excessive current, it will either limit the output or interrupt the circuit to ensure user safety.

Overload Protection

The system automatically detects and limits the amount of excessive power consumed by connected devices to prevent sudden shutdowns and damage to connected devices. This is especially important when powering multiple high-power devices.

Over Temperature Protection

High temperatures reduce battery performance, accelerate battery degradation life, and pose a safety risk. When the BMS monitors that the battery temperature exceeds the safety threshold, the system will initiate cooling measures or shut down the power station.

Low-Temperature Protection

Extreme cold conditions can lead to a decrease in battery charging efficiency. The BMS keeps the battery healthy by restricting the portable power station from charging in freezing temperatures.

Short Circuit Protection

When a short circuit is detected, the system immediately cuts off power to prevent sparks, fire, and permanent battery damage. This is an important safety feature for indoor and outdoor use.

SOH (State of Health) Monitoring Protection

The BMS continuously monitors the health of the battery. Battery performance, efficiency, and longevity are improved by tracking battery data, training learning battery algorithms, and continuously updating battery model characterization data. This allows users to optimize usage and perform maintenance or replacements when needed.

The intelligent BMS system offers eight protection functions that ensure comprehensive battery safety and performance. If the system detects abnormal conditions, it automatically adjusts the output of each component and cuts off the power supply when necessary to prevent damage.

How does the Intelligent BMS work?

Intelligent BMS combines hardware and software to achieve its goal of managing battery health and performance.

Sensors: Measure voltage, current, and temperature in real time.
Microcontrollers: Process sensor data and execute control algorithms.
Intelligent algorithms: Analyze historical data to predict battery behavior and optimize performance.
Communication Interface: Allows the user to monitor battery status through an application or display.
Protection Mechanisms: Regulate the overall energy of the battery and automatically disconnect the battery in the event of a failure.

“Intelligent BMS is the key to the innovation behind modern energy solutions that ensure portable power stations are safe, efficient, and durable.” Mr. Huang, CE-LINK Product Manager, said. “Whether users are camping in the wilderness or preparing for a power outage, the intelligent BMS keeps portable power stations ready to supply power.”

About CE-LINK

Founded in 2004, CE-LINK is a leader in portable power solutions, specializing in innovative and high-quality energy products. Known for its commitment to safety, reliability, and sustainability, CE-LINK continues to push boundaries, delivering solutions that meet the evolving power needs of modern users.

For more information on CE-LINK and its products, visit:

Website: www.ce-link.com

LinkedIn: www.linkedin.com/company/ce-link

Facebook: www.facebook.com/CELINK.ELECTRONICS

YouTube: www.youtube.com/@ce-linkelectronics3909

Media Contact
Company Name: CE LINK LIMITED
Email: Send Email
City: Dongguan
State: Guangdong
Country: China
Website: www.ce-link.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CE-LINK Intelligent BMS System Offers Eight Protection Mechanisms to Guard Battery Safety

New World Forensics Revolutionizes Digital Investigations with Cutting-Edge AI Technology

Miami, FL – March 12, 2025 – New World Forensics, a leader in digital forensic consulting, is transforming the industry with its advanced AI-powered forensic software. As digital evidence becomes increasingly complex and voluminous, the firm is harnessing artificial intelligence to deliver faster, more accurate investigative results.

AI-Powered Innovation in Digital Forensics

In an era where digital data is central to investigations, traditional forensic methods often struggle to keep pace. New World Forensics addresses this challenge by integrating state-of-the-art AI technology into its workflow. AI streamlines the analysis of massive datasets, enabling investigators to:

Rapidly Process Data: AI algorithms sift through terabytes of information in minutes, identifying relevant files and evidence that might take hours or days with manual methods.
Detect Patterns and Anomalies: From uncovering subtle signs of cybercrime to identifying manipulated media like deepfakes, AI enhances the ability to spot critical clues.
Correlate Evidence: By linking information across multiple sources, AI provides a comprehensive view of case data, improving the accuracy of findings.

These capabilities accelerate investigations while ensuring precision, making AI an indispensable tool in modern digital forensics.

Leadership Driving Industry Change

Leading this technological revolution is CEO Juan Ruiz, a veteran with over 20 years in law enforcement and 17 years in forensic consulting. Under his guidance, New World Forensics has become a pioneer in adopting and applying AI to real-world cases. Ruiz’s expertise ensures that the firm not only leverages cutting-edge tools but also tailors them to meet the unique demands of each investigation.

“AI is not just a tool; it’s a game-changer in digital forensics,” said Ruiz. “It allows us to process and analyze data at unprecedented speeds, uncovering critical evidence that might otherwise be missed. Our mission is to provide clients with the most efficient and reliable forensic services available.”

Comprehensive Forensic Solutions

New World Forensics offers a wide range of services, including computer forensics, eDiscovery, and cell phone forensics. By incorporating AI, the firm delivers deeper insights and faster results, supporting clients in fields ranging from law enforcement to corporate litigation. This blend of expertise and innovation positions New World Forensics as a trusted partner in the pursuit of justice.

About New World Forensics

New World Forensics is a premier digital forensic consulting firm based in Miami, FL. With a team of seasoned professionals and advanced technology, the firm provides comprehensive solutions across multiple forensic disciplines, setting the standard for excellence in the industry.

For more information, please contact: Media Relations, Phone: 888-322-4038, Email: media@nwflabs.com, Visit us at www.nwflabs.com

Media Contact
Company Name: New World Forensics
Email: Send Email
Phone: 888-322-4038
Country: United States
Website: www.nwflabs.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New World Forensics Revolutionizes Digital Investigations with Cutting-Edge AI Technology

Triple Negative Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Triple Negative Breast Cancer Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Triple Negative Breast Cancer Treatment Landscape. Click here to read more @ Triple Negative Breast Cancer Pipeline Outlook

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report

In March 2025: Novartis Pharmaceuticals conducted a study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA mutation (Study Part B2).
In March 2025:- Providence Health & Services conducted a study is to establish the safety and tolerability of pembrolizumab when administered in combination with either of two chemotherapy regimens (weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients.
In March 2025:- Rhizen Pharmaceuticals SA announced a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.
DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies.
The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
Promising Triple Negative Breast Cancer Pipeline Therapies such as Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

Stay ahead with the most recent pipeline outlook for Triple Negative Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Triple Negative Breast Cancer Treatment Drugs

Triple Negative Breast Cancer Emerging Drugs Profile

Camrelizumab: Jiangsu HengRui Medicine

Camrelizumab (Airuika) is a humanized monoclonal antibody acts as immunomodulatory agent. It is formulated as solution for intravenous route. Camrelizumab is indicated as third-line treatment for recurrent or refractory classical hodgkin’s lymphoma, advanced hepatocellular carcinoma patients with oxaliplatin system chemotherapy, combined with pemetrexed and carboplatin for epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, non-resectable locally advanced or metastatic first-line treatment of non-squamous non-small cell lung cancer (NSCLC), locally advanced or metastatic esophageal squamous cell carcinoma patients who have previously received first-line chemotherapy and whose disease has progressed or become intolerable and for the treatment of patients with advanced nasopharyngeal carcinoma who had disease progression after previous second-line and above chemotherapy or intolerable treatment. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

SKB264 is an innovative TROP2-directed ADC which was developed by OptiDC, a well-known international ADC R&D platform of Kelun-Biotech, using a proprietary payload-linker strategy (Kthiol design strategy) that achieves an optimized balance of ADC safety and efficacy by combining novel irreversible antibody conjugation chemistry, pH-sensitive payload release mechanisms, and site-specific moderately potent toxin molecules with a DAR of 7.4 (novel topoisomerase I inhibitors). SKB264 has received Breakthrough Therapy Designations (BTDs) from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic triple-negative breast cancer.

AK117: Akeso Biopharma

AK117, independently developed by Akeso, is a next generation of humanized lgG4 anti-CD47 antibody without hemagglutination effect. AK117 can bind to CD47 expressed on tumor cells and block the interaction between CD47 and SIRPα, in order to enhance the phagocytic activity of phagocytes on tumor cells, thereby inhibiting the growth of tumors. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

PLX038: ProLynx

PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC. Top1 inhibitors cause DNA breaks and kill tumors that are unable to repair the damage. Previously, Curie researchers showed that about one-third of TNBC patients have defects in DNA damage repair, and should respond to an effective SN-38-based therapy (Coussy et al., 2020). In PLX038, SN-38 is covalently bound to a circulating nanoparticle and is slowly released to provide free SN-38 with a long half-life, low Cmax, and high exposure – important facets for optimal safety and efficacy. Importantly, in preclinical studies PLX038 was shown to accumulate and be retained in solid tumors, where it slowly releases its SN-38. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

PMD-026: Phoenix Molecular Designs

PhoenixMD’s lead candidate, PMD-026, is the first RSK inhibitor being developed for the treatment of TNBC. It is a pill that is convenient for patients as opposed to intravenous delivery, the mode most commonly used to deliver chemotherapy. PMD-026 was designed for TNBC because RSK2 was specifically identified as the key kinase that drives the growth of this breast cancer subtype5, 6. PMD-026 is well-tolerated in breast cancer patients and can stop tumor growth for up to 5 months based on Phase 1 data. PFS in women with TNBC is three times longer for patients that express high levels of RSK2 activation as compared to those with low RSK2 activation. Preclinical data shows PMD-026 has the potential to be a platform technology for chemotherapy, hormone therapy and/or immunotherapy sensitization for a wide range of refractory cancers in the future. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

The Triple Negative Breast Cancer Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
Triple Negative Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market

Explore groundbreaking therapies and clinical trials in the Triple Negative Breast Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Triple Negative Breast Cancer Drugs

Triple Negative Breast Cancer Companies

Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Parenteral
intravenous
Subcutaneous
Topical

Triple Negative Breast Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Unveil the future of Triple Negative Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Triple Negative Breast Cancer Market Drivers and Barriers

Scope of the Triple Negative Breast Cancer Pipeline Report

Coverage- Global
Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Triple Negative Breast Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Triple Negative Breast Cancer Companies, Key Products and Unmet Needs

Table of Content

Introduction
Triple Negative Breast Cancer Executive Summary
Triple Negative Breast Cancer: Overview
Triple Negative Breast Cancer Pipeline Therapeutics
Triple Negative Breast Cancer Therapeutic Assessment
Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Camrelizumab: Jiangsu HengRui Medicine
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AK117: Akeso Biopharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
PMD-026: Phoenix Molecular Designs
Drug profiles in the detailed report…..
Inactive Products
Triple Negative Breast Cancer Companies
Triple Negative Breast Cancer Products
Triple Negative Breast Cancer Unmet Needs
Triple Negative Breast Cancer Market Drivers and Barriers
Triple Negative Breast Cancer Future Perspectives and Conclusion
Triple Negative Breast Cancer Analyst Views
Triple Negative Breast Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Chile Data Center Market Investment to Reach $1.24 Bn by 2030 – Arizton

“Chile Data Center Market Research Report by Arizton”

Get Insights on 37 Existing Data Centers and 09 Upcoming Facilities across Chile 

According to Arizton’s latest research report, the Chile data center market is growing at a CAGR of 8.27% during 2024-2030.

To Know More, Click: https://www.arizton.com/market-reports/chile-data-center-market

Report Summary     

Market Size – Investment (2030): $1.24 Billion     

Market Size – Area (2030): 230 Thousand Sq. ft.   

Market Size – Power Capacity (2030): 54 MW    

CAGR – Investment (2024-2030): 8.27%      

Colocation Market Size (2030): $375 Million 

Historic Year: 2021-2023     

Base Year: 2024     

Forecast Year: 2025-2030     

Chile Data Center Market Overview

Chile is home to around 37 operational colocation data centers, and the market is expected to grow significantly, positioning the country as a key emerging market for data center development in Latin America. Major operators such as Equinix, Ascenty, ODATA, Scala Data Centers, and Cirion Technologies dominate the market, with several global providers entering through strategic partnerships or acquisitions. For instance, Equinix entered the market in 2022 by acquiring data center facilities from Entel, while Actis acquired Nabiax’s data centers to launch its platform, NextStream. As of 2024, retail colocation holds a dominant 79% market share, with wholesale colocation at 21%. However, by 2030, wholesale colocation is expected to grow to around 40%, driven by increasing demand from cloud operators. Ascenty, one of the leading operators, currently manages two data centers in Santiago, generating over $14.6 million in annualized rent and maintaining a 90.1% occupancy rate. Retail colocation revenues primarily come from telecommunications, media, healthcare, and energy sectors, while wholesale colocation is mainly driven by cloud, IT, and BFSI sectors.

Development Plans in Chile Data Center Market

As of 2024, Santiago remains the primary hub for data center development in Chile, driven by rising demand for cloud, colocation, and digital services. Key operators such as Ascenty, Equinix, SONDA, and GTD have significantly expanded their presence in the city.

Equinix has developed four facilities, adding approximately 81,117 square feet of white floor space in Santiago.
AWS has received approval for a second data center in Huechuraba, set to have a combined area of 198,100 square feet, with the first phase expected by February 2026.
Cirion Technologies plans a new data center, SAN2, in the Quilicura industrial district, expected to be operational by early 2025.
ClaroVTR expanded its Colina data center by adding a 32,300 square feet building, bringing the total space to 53,820 square feet.
Ascenty operates two data centers in Santiago, with a total rentable area of 119,000 square feet by December 2024, and additional development plans for 118,000 square feet, with 71,000 square feet reserved for future expansion.

Chile’s Advancements in Inland and Submarine Connectivity

Chile has significantly enhanced its inland and submarine connectivity, positioning itself as a key data transit hub in South America. The country currently operates 8 submarine cables, with one more expected by 2027, improving global data traffic and regional connectivity. Investments in fiber optic networks and cables like the Humboldt Cable are helping meet the rising demand for broadband and cloud services.

Chile is also conducting a $2.2 million feasibility study for a subsea cable to connect its southernmost province with Antarctica, promoting scientific collaboration and faster data transmission by January 2025. In 2024, Hurricane Electric launched its first Point of Presence (PoP) in Santiago at Ascenty SCL2, enhancing access to high-speed IP transit and global connectivity. The Humboldt submarine cable, launching in January 2024, will directly link Chile with the Asia-Pacific region, boosting digital connectivity and supporting economic growth.

Santiago remains a major hub for data centers, but other regions like Valparaiso and Concepcion are also gaining attention due to their proximity to undersea cable systems. Overall, Chile’s improved connectivity infrastructure strengthens its role as a regional digital hub, fostering economic growth and innovation through faster data exchange and enhanced global integration.

Why Should You Buy this Research?

This research provides a comprehensive analysis of the Chile data center market, including:

Market size, investment details, power capacity, and revenue across the colocation, hyperscale, and enterprise sectors.
Data center investments in square feet and power capacity (MW) across six cities.
Existing and upcoming data centers: 37 existing and 9 upcoming facilities.
Colocation market trends, including revenue forecasts (2021-2030), pricing, and a breakdown of wholesale vs. retail colocation.
Detailed analysis of IT, power, cooling, and construction investments, with forecasts.
Insights on trends, growth opportunities, restraints, and market projections.
Overview of key IT infrastructure providers, contractors, and investors in Chile.
A transparent research methodology focused on demand and supply dynamics.

Buy this Research @ https://www.arizton.com/market-reports/chile-data-center-market

The Report Includes the Investment in the Following Areas:

IT Infrastructure

Server Infrastructure
Storage Infrastructure
Network Infrastructure

Electrical Infrastructure

UPS Systems
Generators
Transfer Switches & Switchgears
PDUs
Other Electrical Infrastructure

Mechanical Infrastructure

Cooling Systems
Racks
Other Mechanical Infrastructure

Cooling Systems

CRAC and CRAH Units
Chillers Units
Cooling Towers, Condensers and Dry Coolers
Other Cooling Units

General Construction

Core & Shell Development
Installation & Commissioning Services
Engineering & Building Design
Fire Detection & Suppression
Physical Security
Data Center Infrastructure Management (DCIM)

Tier Standard

Tier I & Tier II
Tier III
Tier IV

Vendor Landscape

IT Infrastructure Providers

Cisco
Dell Technologies
Hewlett Packard Enterprise
Huawei Technologies
IBM
Lenovo

Data Center Construction Contractors & Sub-Contractors

Aceco TI
AECOM
Constructora Sudamericana
Fluor Corporation
Hyphen
PQC
Turner & Townsend

Support Infrastructure Providers

ABB
ASSA ABLOY
Axis Communications
Bruno
Caterpillar
Cummins
Honeywell International
Johnson Controls
Legrand
Mitsubishi Electric
Munters
Piller Power Systems
Panduit
Rittal
Schneider Electric
Siemens
STULZ
Vertiv

Data Center Investors

Actis (NextStream)
Ascenty
Cirion Technologies
ClaroVTR
EdgeConneX
Equinix
Google
GTD
IPXON Networks
ODATA (Aligned Data Centers)
Scala Data Centers
SONDA

New Entrants

Amazon Web Services
Microsoft

Key Questions Answered in the Report:     

How big is the Chile data center market?

How much MW of power capacity will be added the Chile during 2025-2030?

What is the growth rate of the Chile data center market?

What factors are driving the Chile data center market?

Check Out Some of the Top Selling Reports of Your Interest:     

Brazil Data Center Market – Investment Analysis & Growth Opportunities 2025-2030

https://www.arizton.com/market-reports/brazil-data-center-market-investment-analysis-report-2025

Mexico Data Center Market – Investment Analysis & Growth Opportunities 2025-2030

https://www.arizton.com/market-reports/mexico-data-center-market-investment-analysis

Why Arizton?     

100% Customer Satisfaction     

24×7 availability – we are always there when you need us     

200+ Fortune 500 Companies trust Arizton’s report     

80% of our reports are exclusive and first in the industry     

100% more data and analysis      

1500+ reports published till date     

Post-Purchase Benefit     

1hr of free analyst discussion     
10% off on customization

About Us:     

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.  

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.  

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.  

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/chile-data-center-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chile Data Center Market Investment to Reach $1.24 Bn by 2030 – Arizton

Floor Adhesive Market Report 2025: Highlighting Growth Opportunities, Leading Players, and Market Forecasts through 2028

“Browse 160 market data Tables and 60 Figures spread through 260 Pages and in-depth TOC on “Floor Adhesive Market””

The Floor Adhesive Market is driven by rising construction activities, demand for durable flooring solutions, and eco-friendly adhesive innovations. Growth is fueled by increasing residential and commercial projects, with Asia-Pacific leading the market. Advancements in water-based adhesives further shape industry trends.

The global floor adhesives market size is projected to grow from USD 9.7 billion in 2023 to USD 12.8 billion by 2028, at a CAGR of 5.8%. The market offers a range of floor adhesives tailored to specific flooring materials. The reports 2025 research report offers an analytical view of the industry by studying different factors like floor adhesives market growth, consumption volume, Market Size, Revenue, Market Share, Market Trends, and floor adhesives industry cost structures during the forecast period from 2025 to 2028.

The floor adhesives market is divided into five key regions: North America, Europe, Asia Pacific, the Middle East & Africa, and South America. In terms of demand, Asia Pacific is expected to be the market leader over the forecast period. The floor adhesives market is intrinsically influenced by two pivotal factors: the surge in construction activities fueled by urbanization and the compelling shift towards sustainability and environmentally-friendly construction practices. As the industry responds to these driving forces, strategic alignment and innovation become imperative for capitalizing on the opportunities presented by these factors, ultimately steering the course of the floor adhesives market towards a trajectory of sustainable growth and strategic relevance.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37475603

The tile & stone segment is expected to account for one of the largest shares in 2023.

The tile and stone application segment have emerged as a pivotal catalyst, driving remarkable growth within the floor adhesives market. This surge is underpinned by a strategic interplay of factors that accentuate the significance of tile and stone installations in contemporary construction and design practices. This segment’s extraordinary expansion is a testament to the evolving preferences of consumers, the intrinsic attributes of floor adhesives, and the synergy between aesthetics, functionality, and durability.

One of the key drivers behind the substantial growth in the tile and stone application segment is the prevailing shift in consumer preferences towards these materials. Tiles and stones have garnered significant popularity due to their innate elegance, versatility, and timelessness. As modern design trends veer towards sleek aesthetics and minimalist sensibilities, tiles and stones are preferred choices for creating visually striking and sophisticated spaces. The precision and finesse required in installing these materials necessitate high-performance adhesives that can seamlessly bond these surfaces to subfloors, thereby anchoring the growth trajectory of the tile and stone application segment.

The residential segment is expected to account for the largest share in 2023.

The residential sector is unequivocally emerging as a powerhouse, propelling remarkable growth within the floor adhesives market. This robust upward trajectory finds its roots in a convergence of strategic factors, emblematic of the sector’s pivotal role in shaping the dynamics of the industry. This surge in growth within the residential segment is not a mere coincidence; rather, it is a manifestation of evolving consumer preferences, the relentless surge in housing demand, and the intrinsic alignment between contemporary living standards and the attributes of floor adhesives.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=37475603

Central to this extraordinary growth is the ongoing evolution of consumer preferences, marked by an unyielding pursuit of elevated living standards and personalized interior spaces. In an era characterized by heightened aesthetic consciousness, homeowners and property developers are seeking flooring solutions that harmoniously blend durability, versatility, and visual allure. It is here that floor adhesives come to the fore, celebrated for their adeptness in enabling secure and long-lasting flooring installations. As residential spaces morph into havens of style and functionality, floor adhesives stand as indispensable allies in realizing these aspirations.

Asia Pacific is expected to account for one of the largest share in 2023.

Asia Pacific’s status as the largest consumer of floor adhesives is a testament to its pivotal role in the global economic landscape. The region’s dynamism, underscored by rapid urbanization, cultural diversity, and sustainability imperatives, collectively forges a conducive environment for robust adhesive demand. Industry stakeholders and market participants are poised to capitalize on this lucrative market, capitalizing on the region’s growth trajectory, and strategically aligning their offerings to address the evolving needs of the Asia Pacific floor adhesives market.

Floor Adhesive Market Companies

There are various small, medium, and large players operating in the market. Some of the major market players include Henkel AG (Germany), H.B. Fuller (US), Sika AG (Switzerland), Arkema (Bostik SA) (France), 3M (US), Dow Inc (US), Wacker Chemie AG (Germany), and Pidilite Industries Limited (India). They have adopted various developmental strategies such as investment & expansions, new product launches, mergers & acquisitions, and joint ventures to increase their share in the market.

Arkema (Bostik): Arkema is a global specialized chemical and innovative material producer with four business segments: advanced materials, coating solutions, adhesives, and intermediates. In February 2015, the firm bought Bostik SA (the world’s third-largest industrial adhesives maker) to boost its position in the specialty chemicals sector. Its adhesives are mostly utilized in the building business (both inside and outside). Bostik, the smart adhesives expert, is expanding its technological leadership in the industrial, personal care, construction, and consumer products industries three years after joining Arkema’s high-performance materials business. The corporation has around 55 countries and 144 manufacturing facilities.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=37475603

Wacker Chemie AG: Wacker Chemie AG is a chemical product manufacturer and distributor. Silicones, Polymers, Biosolutions, and Polysilicon are its business segments. Silicones and silicone rubber are used in consumer items, chemicals, energy and electronics applications, and building materials. Dispersions and dispersible polymer powders are produced by the Polymers section. Proteins, cyclodextrins, cysteine, and acetate solid resins are manufactured by the Biosolutions sector. For the semiconductor and electronics sectors, the Polysilicon section includes hyperpure polysilicon, chlorosilanes, and pyrogenic silicas. Other activities are included in the other parts.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Floor Adhesive Market Report 2025: Highlighting Growth Opportunities, Leading Players, and Market Forecasts through 2028

Voted The Best Rated Property Management Company In Toronto Area By Investors And Tenants

The Property Management Company Toronto Real Estate Investors Recommend Most.

Toronto, ON – In an industry often criticized for hidden fees, lack of transparency, and misaligned incentives, Buttonwood Property Management is taking a different approach — one designed from inception to put clients first, including both property owners (landlords) and tenants.

A Mission to Improve Industry Standards

Buttonwood Property Management has always been committed to fairness, transparency, and long-term client relationships. By listening to our clients, we have refined our services to better serve both property owners and tenants, and we encourage other providers to adopt these best practices to improve the industry’s reputation as a whole.

The real estate adage says, “The best time to buy real estate was 20 years ago; the second-best time is today.” While finding the right investment property is crucial, professional property management during the hold period is just as important. A skilled property manager ensures quality tenants who pay on time and maintains the property to protect the owner’s investment.

Buttonwood Property Management’s mission is twofold: helping property owners build real estate wealth over time while ensuring tenants enjoy their stay and feel at home.

Buttonwood Property Management: Redefining Property Management for Owners and Tenants Alike

Eliminating Hidden Fees and Misaligned Incentives

The property management industry is notorious for luring clients in with low monthly fees only to surprise them with hidden costs such as onboarding fees, property visitations, move-in inspections, lease renewals, maintenance markups, and more. Buttonwood Property Management is committed to changing that:

No Hidden Fees: Our monthly management fee covers all necessary services, ensuring full transparency and eliminating unexpected charges.
No Profit from Maintenance: Unlike many competitors, Buttonwood does not add markups to trade invoices. Instead, we pass any trade discounts directly to the property owner. We only succeed when our clients succeed, and we actively work to minimize unnecessary maintenance expenses.
Performance-Based Management Fees: Our management fee is only charged when the property is tenanted and rent is being paid. If a property is vacant or a tenant is not paying rent, we work free of charge—aligning our interests with property owners to maintain occupancy and cash flow.
Loyalty Rewards: Our standard tenant placement fee is one month’s rent plus HST, in line with industry standards. However, we offer a 50% discount on tenant placement fees for landlords who commit to our services for at least two years, saving them over $1,000 on average in Toronto’s rental market.

A Client-Centric Approach to Property Management

Buttonwood Property Management helps real estate investors identify and acquire profitable investment properties, find and retain great tenants, and maintain strong relationships with all involved parties. Our expert team is dedicated to:

Understanding and addressing tenant needs to foster trust and cooperation.
Maintaining properties to preserve and enhance asset value.
Offering comprehensive residential property management services across Toronto, covering condos, townhomes, single-family homes, duplexes, triplexes, and multiplex properties.

Our team is hyper-focused on what matters most: delivering peace of mind to property owners while creating comfortable, well-managed homes for tenants.

About Buttonwood Property Management

Buttonwood Property Management is a leading property management company in Toronto, providing comprehensive residential property management services. With a commitment to transparency, fairness, and exceptional service, we help property owners achieve long-term success while ensuring tenants enjoy a high-quality rental experience.

Media Contact
Company Name: Buttonwood Property Management Inc.
Contact Person: Sabine Ghali
Email: Send Email
Phone: (416) 835-7191
Address:2 St Claire Street West Suite 1800
City: Toronto
State: Ontario
Country: Canada
Website: www.buttonwood.ca

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Voted The Best Rated Property Management Company In Toronto Area By Investors And Tenants

AquaOrange Delivers Unmatched IT Support Services to Empower Thai Businesses

AquaOrange’s IT Support Services empower Thai businesses with fast, reliable, and localized IT solutions. By reducing downtime and optimizing systems, AquaOrange helps companies thrive in today’s competitive landscape.

AquaOrange, a leading provider of IT solutions in Thailand, is redefining IT Support Services to help businesses thrive in an increasingly competitive and technology-driven landscape. With a strong focus on speed, reliability, and localized expertise, AquaOrange ensures seamless operations for organizations of all sizes.

Modern businesses depend on reliable IT infrastructure to remain competitive. AquaOrange’s IT Support Services provide comprehensive solutions tailored to meet these needs, from troubleshooting and system optimization to on-site and remote support. This client-focused approach minimizes downtime and enhances productivity, enabling businesses to operate without disruption.

AquaOrange’s local team of skilled IT professionals has a fast response time and delivers personalized service. By understanding the unique challenges faced by Thai businesses, AquaOrange offers solutions that are both effective and practical.

“Our IT Support Services are designed to empower businesses with reliable technology infrastructure,” said Shahan Farid, CEO of AquaOrange. “We are committed to helping our clients overcome technical challenges, so they can focus on growing their business.”

In addition to day-to-day support, AquaOrange integrates advanced tools like endpoint monitoring and real-time issue detection, ensuring potential problems are addressed before they escalate. Businesses have reported significant improvements, including up to a 40% reduction in IT-related downtime.

Recent success stories include a logistics company that relied on AquaOrange to streamline its IT operations during a high-demand period. With AquaOrange’s expert support, the company maintained uninterrupted services and improved operational efficiency.

Companies looking to strengthen their IT infrastructure can explore AquaOrange’s services by visiting www.aquaorange.co.th or reaching out directly to the team.

About AquaOrange

AquaOrange is a premier IT solutions provider in Thailand, specializing in IT Support Services, cloud services, endpoint security, and more. With fast, reliable service and a commitment to local expertise, AquaOrange helps businesses to achieve their goals efficiently and securely.

Media Contact
Company Name: AquaOrange Software Co., Ltd.
Email: Send Email
Phone: +66 (0)2-120-1414
Address:1 The Empire Tower, Sathorn 47th Floor
City: Bangkok 4703
Country: Thailand
Website: www.aquaorange.co.th

St. Bonaventure University’s Online Ed.D. Program: Transforming Educational Leadership

St. Bonaventure University launches a new online Doctor of Education (Ed.D.) program, designed to redefine educational leadership with flexibility, high quality, and values-driven learning.

With a strong foundation in educational leadership theory and practice, St. Bonaventure’s online Ed.D. program equips aspiring leaders with the insights and strategies needed to drive systemic change in schools, districts, and other educational organizations. This practitioner-focused program removes geographic and scheduling barriers, allowing students to pursue their doctoral studies from anywhere at their own pace.

This online doctorate in educational leadership offers an innovative curriculum that blends cutting-edge educational leadership theories with practical, real-world approaches for addressing contemporary educational challenges. Students engage in meaningful applied research, gain new insights into leadership and policy analysis, all framed by the Franciscan values of compassion, wisdom, and integrity.

Key Features of the Online Ed.D. Program:

Flexibility & Accessibility: Designed for working professionals, the 100% online format promotes individually paced learning, offering convenience so students can balance commitments with their academic journey. The flexibility of asynchronous online coursework allows students to advance their education without compromising their career or personal responsibilities.
Ethical Leadership & Informed Decision-Making: The program places a strong emphasis on ethical leadership, empowering graduates to make data-driven decisions that improves both individual learning and larger educational systems. Students are equipped to leverage applied research to solve problems of practice and address the pressing challenges facing today’s dynamic educational landscape.
Real-World Relevance: Students engage with contemporary issues in their work environments, with a flexible dissertation process that offers three distinct options. This feature allows students to tailor their research to their professional aspirations and areas of interest, demonstrating their capacity to address problems of practice in the field.
Experienced Faculty & Mentorship: Students receive personalized mentorship from experienced faculty, guiding them through their academic journey. The program fosters a collaborative online learning environment, enriched by virtual discussions, peer reviews, and real-time feedback, ensuring students receive continuous support and professional growth.
Academic Excellence & Recognition: St. Bonaventure University is consistently recognized for its transformative educational experience. Ranked 8th for value, 19th among regional universities in the North, and 76th for social mobility by U.S. News & World Report in 2025, the university stands out for its commitment to student success and promoting accessibility in education.

The online edd program prepares graduates for leadership roles in a variety of educational settings, including K-12 schools, school districts, higher education institutions, and policy organizations. Graduates are equipped to pursue positions such as educational administrators, district leaders, policy analysts, and researchers, where they can apply their advanced knowledge and leadership skills to influence positive change and shape the future of education.

The program’s curriculum blends innovative theory with real-world application. With a focus on applied research, ethical leadership, and improving both individual learning and larger educational systems, the culminating dissertation work provides the opportunity for students to improve learning, transform policy, and refine the latest approaches to educational leadership. St. Bonaventure’s long-standing commitment to academic excellence ensures that students receive the support and resources they need to succeed, including career services, academic advising, and access to an extensive alumni network.

For more information, visit https://online.sbu.edu/programs/doctorate/doctor-educational-leadership.

About the Organization:

The nation’s first Franciscan university, St. Bonaventure University is a community committed to transforming the lives of our students inside and outside the classroom, inspiring in them a lifelong commitment to service and citizenship. St. Bonaventure University is accredited by the Middle States Commission on Higher Education.

Media Contact
Company Name: St. Bonaventure University
Email: Send Email
Phone: (585) 314-0321
Address:3261 West State Road
City: St. Bonaventure
State: NY
Country: United States
Website: https://online.sbu.edu/